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Conclusions: BAV can be utilized as a part of a complex therapy in severe AS in high
risk patients. EBRT has no impact on prevention of restenosis after BAV.
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Background: To determine the effect of transfemoral aortic valve implantation (TF-
TAVI) on plasma BNP levels and to evaluate their predictive value for 30-day and
one-year survival.
Methods: Baseline BNP, peak BNP within 48 hours after TAVI and predischarge BNP
were obtained in 104 patients who underwent TF-TAVI with complete one-year
follow-up.
Results: BNP was elevated at baseline (298.2, IQR 145.8, 661.6 pg/ml) and showed an
acute increase after TF-TAVI (508.9, IQR 253.3, 868.6 pg/ml) followed by regression
towards baseline levels prior to discharge (327.2, IQR 159.2, 634.6 pg/ml), p 0.001.
Acute BNP increase (BNPpeak–baseline) is significantly higher in 30 days non-
survivors (277.1 IQR 252.1, 810 pg/ml) than in survivors (132.8 IQR10.1, 301 pg/ml),
p 0.028, and is found to be independent predictor of 30 days survival. Kaplan-Meier
(KM) survival analysis showed a reduced 30 days survival in patients with a BNPpeak–
baseline  248.9 pg/ml, p 0.002. For 1-year survival, predischarge BNP level (250.8,
IQR 152.9, 621.8 pg/ml in survivors vs. 591, IQR 354.5, 788 pg/ml in non survivors, p
0.003) and BNPdischarge-baseline(211.8 IQR 521.5, 91.1 pg/ml in survivors vs.
108.4 IQR 12.2, 272.6 pg/ml in non survivors, p0.002) are independent predictors. KM
analysis showed that 1-year survival is significantly lower in patients with a predischarge
BNP 327.2 and a BNPdischarge-baseline  38.3 than in those not fulfilling both
criteria, p 0.001.
Conclusions: BNP values are elevated in patients with severe, symptomatic aortic
stenosis presenting for TF-TAVI. They further increase acutely after procedure and
regress to baseline levels, usually prior to hospital-discharge. Acute, postprocedural BNP
increase is an independent predictor of reduced 30 days survival, while reduced 1-year
survival is predicted by higher predischarge BNP levels and failure of BNP to decline at
discharge below baseline BNP level.
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Background: Transcatheter aortic valve implantation (TAVI) is an accepted alternative
in high-risk or inoperable patients with severe, symptomatic aortic stenosis. The
trans-femoral (TF) approach is most widely used however is limited in those with
peripheral vascular disease. The trans-apical (TA) and trans-axillary (TAx) approaches
have been described for such patients with limited data on outcomes. This study reports
our single center experience with both approaches and compares patient outcomes.
Methods: A retrospective study of patients undergoing TAVI from January 2010 to
December 2011. Procedural and clinical outcomes were defined according to the VARC
definitions.
Results: During the study period, 126 patients underwent TAVI at our hospital; 70 (55%)
patients were done by TF, 41 (33%) by TA and 15 (12%) by the TAx. Indications for TAx
or TA approach for TAVI in our institution were as follows: PVD in 34 patients (61%),
suboptimal size of femoral arteries (arterial diameter6 mm) in 23 (41%), AAA in 14
(25%), morbid obesity in 8 (14%). Procedural success, defined as implantation of the
device with a reduction in aortic valve gradient and without the need for conversion to
open heart surgery, was 93% (14/15) in TAx and 88% (36/41) in TA (p1.00). In TAx
group, two patients required retrieval of the devices and subsequent successful implan-
tation of another valve with the same approach. Valve embolization occurred in three TA
cases requiring conversion to conventional AVR.
Table 1: Baseline Characteristics, and Outcomes of TAVI Patients
(TAx and TA)
Baseline Characteristics TAx N (%) TA N (%) P value
Patients 15 41 -
Age (years), mean 	/ SD 81	/7.92 80	/5.99 0.68
Male 13 (87) 22 (54) 0.03
Diabetes 6 (40) 16 (39) 0.95
Morbid obesity, BMI 35 2 (13) 6 (15) 1.00
Peripheral vascular disease 8 (53) 27 (66) 0.39
Abdominal aortic aneurysm 6 (40) 8 (20) 0.12
Diameter of femoral arteries
6mm
6 (40) 17 (41) 0.92
Previous stroke/TIA 2 (13) 4 (10) 0.70
NYHA functional class III-IV 13 (87) 37 (90) 0.65
Outcomes
Successful procedure 14 (93) 36 (88) 1.00
In-hospital all-cause mortality 0 (0) 2 (5) 1.00
30-day all-cause mortality 0 (0) 5 (12) 0.31
Stroke/TIA 0 (0) 0 (0) -
Transfusions 4 (27) 20 (49) 0.23
Minor bleeding complication 3 (20) 7 (17) 1.00
Major bleeding complication 1 (7) 7 (17) 0.43
Life-threatening or disabling bleeding 0 (0) 5 (12) 0.31
Minor vascular complication 1 (7) 1 (2) 0.47
Major vascular complication 0 (0) 1 (2) 1.00
Conclusions: In this single center series the trans-axillary approach was associated with
a trend towards higher procedural success, lower all-cause mortality and fewer bleeding
complications than the trans-apical approach in patients with severe aortic stenosis. Larger
randomized controlled trials will be required to determine the true superiority of one
access site over the other.
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Background: Balloon valvuloplasty (BV) before transcatheter aortic implantation of the
prosthesis has been considered a mandatory step before valve implantation. However, BV
has been associated with complications such as atrioventricular block, aortic insufficiency
and stroke. We report 10 patients with severe aortic stenosis in whom direct transfemoral
implantation of the SAPIEN XT was performed.
Methods: From November 2011 to April 2012, 10 patients (33% of patients treated with
Edwards SAPIEN XT in that period were selected that met the following criteria:
moderate calcification, homogeneous distribution of calcium, symmetrical opening of the
valve and some degree of aortic insufficiency. The valve positioning was guided by TEE
in all cases.
Results: All patients had symptomatic aortic stenosis of a native valve and high risk
surgical; echocardiographic characteristics were: aortic annulus diameter ranged from 17
to 24 mm (determined by TEE). Six patients had the valve midly calcified, in four patients
the degree of calcification was moderate. All patients had symmetric opening of the
stenotic aortic valve. Mild aortic regurgitation was present in seven patients, moderate in
two and trivial in one. The native valve was crossed and the prosthetic aortic valve was
properly positioned in all cases and implanted in the correct position in all cases. No
patient underwent post-dilatation and only 1 patient had a mild periprosthetic regurgita-
tion. There were no adverse events (death, need for pacemaker, myocardial infarction or
stroke). At 30 days postprocedure all patients had significant clinical improvement.
Conclusions: Direct implantation of Edwards SAPIEN XT without prior balloon
valvuloplasty in selected cases is feasible and safe. The number of patients in whom this
technique is applicable and their impact on reducing complications has to be determined.
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